Akademik Veri Yönetim Sistemi
BIOMEDICINES, cilt.12, sa.5, ss.1-13, 2024 (SCI-Expanded)
Abstract: (1) Background: The introduction of novel therapies has led to a considerable evolution
in the management of Multiple Myeloma, and chromosomal abnormalities predict the success of
treatment. We aimed to characterize cytogenetic abnormalities for risk stratification in the patient
population and to evaluate the predictive and prognostic value of the specified abnormalities in
distinct treatment modalities. (2) Methods: This study included patients with Multiple Myeloma who
applied to the Internal Medicine Clinic of the Cukurova University Faculty of Medicine. Between
2010 and 2023, 98 cases with cytogenetic abnormality data were identified. We analysed the effects of
cytogenetic abnormalities on survival and response rates to first chemotherapies. (3) Results: P53 del
was the most prevalent abnormality, and t(11;14) was the most common translocation. There was
no significant difference in the mean survival and treatment response rates for specific cytogenetic
abnormalities. When chemotherapies based on lenalidomide were initiated, patients’ life-death
statuses differed significantly from those of treatments without lenalidomide. Regardless of the
type of chromosomal aberration, lenalidomide-based treatments independently enhanced average
survival 14-fold, while there was no significant difference in overall survival among treatments.
(4) Conclusions: In individuals with cytogenetic abnormalities, lenalidomide-based treatments
should be started regardless of the chemotherapy to be used for the condition.
Keywords: multiple myeloma; cytogenetic abnormalities; immunomodulators